Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Status:
Unknown status
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral
infections. The purpose of this study is to evaluate the safety and antiviral effects of
several different doses of PEG-rIL-29 (a man-made form of IL-29) when it is given in
combination with daily oral doses of ribavirin (an antiviral drug) to subjects with hepatitis
C infection who have received no prior treatment for this disease.